Application of recombinant saccharomyces cerevisiae to production of homoeriodictyol 7-O-glucoside by using glucose

By constructing heterologous synthesis pathways and optimization strategies in Saccharomyces cerevisiae, the production problem of 7-O-glucoside of the high-efficiency biosynthesis is achieved, and the yield is improved and the safety and sustainability of traditional methods are solved. question.

CN119082239AInactive Publication Date: 2024-12-06BLUE OCEAN NEW MATERIALS (TONGZHOU BAY) CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411267042.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively produce 7-O-glucosides of the genus 7-O-glucoside. Traditional methods such as chemical synthesis have safety and sustainability problems, and biosynthetic pathways have not been disclosed.

Method used

By constructing a heterologous synthesis pathway in Saccharomyces cerevisiae, screening key glycosyltransferases, knocking out endogenous glycoside hydrolase, regulating NADPH and UDP-glucose regeneration pathways, optimizing cell growth and fermentation strategies, realizing 7-O of the savonol 7-O -Deadline synthesis of glucosides.

Benefits of technology

The biosynthesis of 7-O-glucoside of sago 7-O-glucoside was achieved, yield was improved, the synthesis pathway was optimized, and the safety and sustainability of traditional methods were solved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005039429590000241
    Figure BDA0005039429590000241
  • Figure BDA0005039429590000251
    Figure BDA0005039429590000251
  • Figure HDA0005039429880000011
    Figure HDA0005039429880000011
Patent Text Reader

Abstract

The invention relates to the field of bioengineering, in particular to application of recombinant saccharomyces cerevisiae to production of homoeriodictyol 7-O-glucoside by using glucose. The invention provides an application of an integration site as a target spot in preparation of homoeriodictyol 7-O-glucoside. And the integration sites comprise one or more of PDC5, TKL2-TEF2, YHRCdelta14, YORWdelta17, ARO10, YNRCdelta9, YERCdelta8, HO, YMRWdelta15, YARCdelta8 and YCRWdelta12, and the integration sites comprise one or more of the following components: the PDC5, the TKL2-TEF2, the YHRCdelta14, the YORWdelta17, the ARO10, the YNRCdelta9, the YERCdelta8, the HO, the YMRWdelta15, the YARCdelta8 and the YCRWdelta12. According to the invention, the de novo synthesis of homoeriodictyol 7-O-glucoside is realized by constructing a heterologous synthesis pathway in saccharomyces cerevisiae, screening key glycosyl transferase, knocking out endogenous glycoside hydrolase, regulating NADPH (nicotinamide adenine dinucleotide phosphate) and a UDP-glucose regeneration pathway, and optimizing cell growth and fermentation strategies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of bioengineering, and in particular to the application of recombinant saccharomyces cerevisiae in producing homoeriodictyol 7-O-glucoside by utilizing glucose. Background Art

[0002] Flavonoids are aromatic natural compounds with important biological activities, such as anti-cancer, anti-inflammatory, and antiviral effects. Flavonoid glycoside products have better biological activities, such as anti-HIV activity and tyrosinase inhibition. Flavonoid glycosides also have stronger solubility and bioavailability and lower cytotoxicity. Homoeriocarbamide 7-O-glucoside is the product of glycosylation of the 7-hydroxyl group of homoeriocarbamide. In addition to the inherent value of flavonoid glycosides, it also has the effect of bitter masking and is widely used in the food and pharmaceutical industries. Therefore, it is crucial to develop sustainable access to homoeriocarbamide 7-O-glucoside. Traditional acquisition methods mainly include chemical synthesis and plant extraction. However, the seasonality and accessibility of plants make plant extraction methods uncommercial, and the use of toxic reagents and extreme reaction conditions make chemical synthesis methods unsafe and unsustainable. Therefore, biosynthesis of homoeriocarbamide 7-O-glucoside has become a potential production method due to its advantages such as short process cycle, high efficiency, and environmental friendliness.

[0003] The biosynthetic pathway of homoeriodictyol 7-O-glucoside has not yet been revealed, but the biosynthetic pathway of the important precursor homoeriodictyol has been studied more thoroughly. According to the existing research ideas, the Saccharomyces cerevisiae cell factory can realize the synthesis of homoeriodictyol from p-coumaric acid, and its pathway mainly includes 4-p-coumaryl-CoA ligase 4CL from parsley, chalcone synthase CHS from petunia, chalcone isomerase CHI from alfalfa, flavonoid 3'-monooxygenase F3'H and cytochrome P450 reductase ATR1 from Arabidopsis, and 3'-O-methyltransferase ROMT-9 from Japanese rice. Using metabolic engineering strategies and rational design and modification of enzymes, the titer of homoeriodictyol in shake flask fermentation can reach 1.0mmol / l. For the de novo synthesis of homoeriocarbazone, the current technology has constructed a de novo synthesis route with ferulic acid as an intermediate in an Escherichia coli cell factory. The pathway contains 4CL from grapes, CHS from Arabidopsis thaliana, and CHI from Arabidopsis thaliana. This technology did not optimize the cell factory and used glycerol as the carbon source to obtain a homoeriocarbazone titer of 17 mg / L. Summary of the invention

[0004] In view of this, the present invention provides an application of recombinant Saccharomyces cerevisiae to produce homoeriodictyol 7-O-glucoside using glucose. The present invention achieves the de novo synthesis of homoeriodictyol 7-O-glucoside by constructing a heterologous synthesis pathway in Saccharomyces cerevisiae, screening key glycosyltransferases, knocking out endogenous glycoside hydrolases, regulating NADPH and UDP-glucose regeneration pathways, and optimizing cell growth and fermentation strategies.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides the use of an integration site as a target in the preparation of homoeriodictyol 7-O-glucoside;

[0007] The integration sites include: one or more of a PDC5 site, a TKL2-TEF2 site, a YHRCdelta14 site, a YORWdelta17 site, an ARO10 site, a YNRCdelta9 site, a YERCdelta8 site, a HO site, a YMRWdelta15 site, a YARCdelta8 site and a YCRWdelta12 site.

[0008]

[0009] In some embodiments of the present invention, in the above application, the sequence of the TKL2-TEF2 site is as shown in SEQ ID NO: 25: aacatcaatcatgcggttgc.

[0010] In some embodiments of the present invention, in the above application, the sequence of the YHRCdelta14 site is as shown in SEQ ID NO:26: tggcgaatgttttgataacttgataactgctggtatttcattgttgaaaaggcatgatattagatgcacaaagtatattataacttatgatcagagatataggaacaaaaaaaagggaaaattcatatctatatgtgaaaataccattatttcctctcctgtttaatattctgtccttaatt ttcatattacattatcaacttttgcatttcagtgtccattaaatcttgggaccattttctcaatcttcatgtcgtcttttcacaccgtatataatatactgg tactataagtactagtcgatagatcgcagttgagtcttattccaaca.

[0011] In some embodiments of the present invention, in the above application, the sequence of the YORWdelta17 site is as shown in SEQ ID NO:27: ttgttggaataaaaatcaactatcatctactaactagtatttacgttactagtatattatcatatacggtgttagaagatg acgcaaatgatgagaaatagtcatctaaattagtggaagctgaaacgcaaggattgataatgtaataggaccaatgaatattaacatataaaat gatgataataatatttatagaattgtagaattgcagattcccttttacggattcctaaatcctcgaggagaacttctagtacattctacataccta atattattgccttattaaaaatggaatcccaacaattatctcaaaattcacccactcttc.

[0012]

[0013] In some embodiments of the present invention, in the above application, the sequence of the YNRCdelta9 site is as shown in SEQ ID NO:29: gagacattttttgggattaattgtttataaaagctatgaacttaggtctacagaatgtaccaaaagttatcctgtaggatata ggaatctacgaaaggggcccgatacttctatataatatatatttttatttctccttcaattttatacgttgtcattccttatcctattacttcatcaattctt gcaattcaacatccaataactttgataactgtttcccatcaattatgtcgtcattttacactgtatatgatacaagtagtatgagtacacaccaatagatgattaattttttc.

[0014] In some embodiments of the present invention, in the above application, the sequence of the YERCdelta8 site is as shown in SEQ ID NO:30: Tgagaaactggcgagtaatttgataattgttcggattgcattgttgccgaatcctataacattaggtatacatagtatacaagcaattctcccgacgttataggaattcacaaaagagaatcgatggtgttactttatcttccttcccgttatactttgtctttcattatcctattagatta catttcagtttccatcaatttttgatggctgtctctcaatt.

[0015] In some embodiments of the present invention, in the above application, the sequence of the HO site is as shown in SEQ ID NO:31: cacaactcttatgaggcccg.

[0016] In some embodiments of the present invention, in the above application, the sequence of the YMRWdelta15 site is as shown in SEQ ID NO:32: tgttggaataacaatcaactatcatccattcactggtatcaatattactggtatattatcttatatggtgtaggaagatgg cataatattgagaaacggctatcggatgtggtaaaagctaaaatgcgaagattgataatgtaacaggatagtgaacgacaacgcataaaatg gaaaaagaggtaatatcgttattatgtaaaattatttgtcctttgtggactctaagatccttg.

[0017] In some embodiments of the present invention, in the above application, the sequence of the YARCdelta8 site is as shown in SEQ ID NO:33: Tggcgaatgttttgataacttgataactgctgatatttcattgttgaaaaggcatgatattagatgcacaaagtatattataacttattatcagagatataggaacaaaaaaaaaagggaaattcatatctatatgtgaaaataccattatttcctcttctatttaatatactgtccttaattt tcatattacattatcaacttttgcatttcagtgtccattaaatcttgggaccattttctcaatcttcatgtcgtgttttcacaccgtatataatatactggt aatataagtactagtcgatagatcgcagttgagtcttatcccaaca.

[0018] In some embodiments of the present invention, in the above application, the sequence of the YCRWdelta12 site is as shown in SEQ ID NO:34: Cgatgaaataaaatcctgatatcatctatatagtagtactcacgttactagtatatcatctataagatgtaggaaaatgtcataagaaatgagaaacagtcattaaatttaatggaaacgaaatgcaaggattggtgatgagataagataatgaaacatagaaaacgaaagg agaaataacagtagtattattattattattattattatgtagaaatattgactctctcttgtagattcatatatcttcaaggggaacttcttgtacattttgtat acctatattatagcgtttaacaacaatggaatcccaacaattaccaaaattttcacacattcctca.

[0019] The present invention also provides the use of expressed genes and / or knocked-out genes in the preparation of homoeriodictyol 7-O-glucoside;

[0020] The expressed genes include: exogenous expressed genes and / or endogenous expressed genes;

[0021] The exogenous expression genes include: TAL gene, PAL gene, C4H gene, ATR2 gene, aroL gene, PDH1 gene, ROMT-9 N135T / I324M one or more of gene, MTHFR gene, UGT73C6 gene, 4CL gene and VHb gene;

[0022] The endogenous expression genes include: CYB5 gene, ARO4 K229L Gene, ARO7 G141S one or more of gene, MET6 gene, SAH1 gene, ADO1 gene, MET13 gene, GND1 gene, Pos5Δ17 gene, PGM1 gene and UGP1 gene;

[0023] The knockout genes include: EXG1 gene and / or HUT1 gene.

[0024] In some embodiments of the present invention, in the above application, the TAL gene has:

[0025] (1), the nucleotide sequence shown in SEQ ID NO: 1; or

[0026] (2) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (1), and having the same or similar function as the nucleotide sequence shown in (1); or

[0027] (3) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (1) or (2); or

[0028] The PAL gene has:

[0029] (4) the nucleotide sequence shown in SEQ ID NO: 2; or

[0030] (5) a nucleotide sequence obtained by substituting, deleting or adding one or more bases of the nucleotide sequence shown in (4), and having the same or similar function as the nucleotide sequence shown in (4); or

[0031] (6) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (4) or (5); or

[0032] The C4H gene has:

[0033] (7), the nucleotide sequence shown in SEQ ID NO: 3; or

[0034] (8) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as the nucleotide sequence shown in (7); or

[0035] (9), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (7) or (8); or

[0036] The ATR2 gene has:

[0037] (10), the nucleotide sequence shown in SEQ ID NO: 4; or

[0038] (11) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (10), and having the same or similar function as the nucleotide sequence shown in (10); or

[0039] (12) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (10) or (11); or

[0040] The CYB5 gene has:

[0041] (13), the nucleotide sequence shown in SEQ ID NO: 5; or

[0042] (14) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (13), and having the same or similar function as the nucleotide sequence shown in (13); or

[0043] (15) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (13) or (14); or

[0044] The ARO4 K229L Genes have:

[0045] (16), the nucleotide sequence shown in SEQ ID NO: 6; or

[0046] (17) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (16), and having the same or similar function as the nucleotide sequence shown in (16); or

[0047] (18), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (16) or (17); or

[0048] The ARO7 G141S Genes have:

[0049] (19), the nucleotide sequence shown in SEQ ID NO:7; or

[0050] (20) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (19), and having the same or similar function as the nucleotide sequence shown in (19); or

[0051] (21), a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (19) or (20); or

[0052] The aroL gene has:

[0053] (22), the nucleotide sequence shown in SEQ ID NO: 8; or

[0054] (23) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (22), and having the same or similar function as the nucleotide sequence shown in (22); or

[0055] (24), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (22) or (23); or

[0056] The PDH1 gene has:

[0057] (25), the nucleotide sequence shown in SEQ ID NO:9; or

[0058] (26) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (25), and having the same or similar function as the nucleotide sequence shown in (25); or

[0059] (27) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (25) or (26);

[0060] The UGT73C6 gene has:

[0061] (28), the nucleotide sequence shown in SEQ ID NO: 10; or

[0062] (29) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (28), and having the same or similar function as the nucleotide sequence shown in (28); or

[0063] (30), a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (28) or (29);

[0064] The GND1 gene has:

[0065] (31), the nucleotide sequence shown in SEQ ID NO: 11; or

[0066] (32) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (31), and having the same or similar function as the nucleotide sequence shown in (31); or

[0067] (33) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (31) or (32);

[0068] The Pos5Δ17 gene has:

[0069] (34), the nucleotide sequence shown in SEQ ID NO: 12; or

[0070] (35) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (34), and having the same or similar function as the nucleotide sequence shown in (34); or

[0071] (36) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (34) or (35);

[0072] The PGM1 gene has:

[0073] (37), the nucleotide sequence shown in SEQ ID NO: 13; or

[0074] (38) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (37), and having the same or similar function as the nucleotide sequence shown in (37); or

[0075] (39), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (37) or (38);

[0076] The UGP1 gene has:

[0077] (40), the nucleotide sequence shown in SEQ ID NO: 14; or

[0078] (41) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (40), and having the same or similar function as the nucleotide sequence shown in (40); or

[0079] (42), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (40) or (41);

[0080] The VHb gene has:

[0081] (43), the nucleotide sequence shown in SEQ ID NO: 15; or

[0082] (44) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (43), and having the same or similar function as the nucleotide sequence shown in (43); or

[0083] (45) A nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (43) or (44).

[0084]

[0085]

[0086]

[0087]

[0088] In some embodiments of the present invention, in the above application, the sequence of the CYB5 gene is as shown in SEQ ID NO:5: Atgcctaaagtttacagttaccaagaagttgccgaacacaatggcccagaaaatttctggattatcatcgatgacaaagtttacgat gtttctcaattcaaagatgaacatccaggtggtgatgaaattataatggatttgggtggacaagatgctacagaaagctttgtcgatatcggtca ttctgacgaagcattgagactactgaaaggtttatacattggtgacgttgacaagaccagtgagcgcgtttctgtggaaaaggtatctacctctgaaaaccaaagtaaaggtagtggtacattggttgtcatattggccattttaatgctaggtgttgcttattatttgttgaacgaataa.

[0089] In some embodiments of the present invention, the ARO4 K229L

[0090] In some embodiments of the present invention, in the above application, the ARO7 G141S gene has the sequence shown in SEQ ID NO:7: Atggatttcacaaaaccagaaactgttttaaatctacaaaatattagagatgaattagttagaatggaggattcgatcatcttc aaatttattgagaggtcgcatttcgccacatgtccttcagtttatgaggcaaaccatccaggtttagaaattccgaattttaaaggatctttcttggattgggctctttcaaatcttgaaattgcgcattctcgcatcagaagattcgaatcacctgatgaaactcccttctttcctgacaagattcagaaatcattcttaccgagcattaactacccacaaattttggcgccttatgccccagaagttaattacaatgataaaataaaaaaagtttatattgaaaagattataccattaatttcgaaaagagatggtgatgataagaataacttcggttctgttgccactagagatatagaatgtttgcaaagcttgagtaggagaatccactttggcaagtttgttgctgaagccaagttccaatcggatatcccgctatacacaaagctgatcaaaagtaaagatgtcgaggggataatgaagaatatcaccaattctgccgttgaagaaaagattctagaaagattaactaagaaggctgaagtctatggtgtggaccctaccaacgagtcaggtgaaagaaggattactccagaatatttggtaaaaatttataaggaaattgttatacctatcactaaggaagttgaggtggaatacttgctaagaaggttggaagagtaa.

[0091] In some embodiments of the present invention, in the above application, the sequence of the aroL gene is as shown in SEQ ID NO:8: Atgacacaacctctttttctgatcgggcctcggggctgtggtaaaacaacggtcggaatggcccttgccgattcgcttaaccgtcggt ttgtcgataccgatcagtggttgcaatcacagctcaatatgacggtcgcggagatcgtcgaaagggaagagtgggcgggatttcgcgccagagaaacggcggcgctggaagcggtaactgcgccatccaccgttatcgctacaggcggcggcattattctgacggaatttaatcgtcacttcatgcaaaataacgggatcgtggtttatttgtgtgcgccagtatcagtcctggttaaccgactgcaagctgcaccggaagaagatttacggccaaccttaacgggaaaaccgctgagcgaagaagttcaggaagtgctggaagaacgcgatgcgctatatcgcgaagttgcgcatattatcatcgacgcaacaaacgaacccagccaggtgatttctgaaattcgcagcgccctggcacagacgatcaattgttga。

[0092] In some embodiments of the present invention, in the above application, the sequence of the PDH1 gene is as shown in SEQ ID NO:9: ATGTCATCTTCTTCTAAGAGCTTAAAGATCGGTATTGTTGGTTTCGGTACATTT GGTCAATTTCTAGCAAACACCATGATCAAGCAAGGTCATACTTTGACCGCTACCTCAAGAACTGATTATTCTCAATTGTGTGATCAAATGGGTATTCATTTCTTTAGAGACATTACTGCATTTCTTGATGCTGATATGGATGTTATCTTGTTGTGTACCAGTATTTCTTCTTTGTCTGAAGTCGTTGGTTCTATGCCATTAGCATGTCTGAAGAGACCAACCTTGTTCGTTGATGTGTTGTCAGTTAAAGAGCATCCAAAGAATCTGCTATTGAAGGTCTTGCCAGAAGAATCTGACATCTTGTGTACTCATCCAATGTTTGGTCCAGTCTCTGGTAAGAATGGTTGGCAGAATTTGACTTTCATGTTCGACAAAGTTAGAATTAAAGATGAAGTCACTTGCTCTAAATTCTTGCAAATCTTTGCTTCAGAAGGTTGTAAGATGGTGGAAATGAGCTGTGAAGAACATGATAAAGCTGCTGCTAAGAGTCAATTCATTACTCATACCATTGGTAGAACTTTGGCTGAAATGGACATCAAATCAACTCCAATTGATACCAAGGGTTTCCAAACTCTGGTTGAATTGAAGAAGCCTGTTATGGGTTGTAGTTTCGATTTGTATTCTGGCTTATTTGTCTACAATAGATTTGCTAGACAAGAGTTGGAGAACTcGGAACATGCATTGCATAAGGTGAAAGAAATGTTGGTGCAAAGAATCGATGAAGGTCAGAATCCAGAAAGAACAGAATCATAA。

[0093]

[0094]

[0095]

[0096]

[0097]

[0098] In some embodiments of the present invention, in the above application, the sequence of the VHb gene is as shown in SEQ ID NO: 15: ATGTTAGACCAACAGACAATCAACATCATTAAAGCAACAGTTCCAGTGTTGAA AGAACATGGTGTCACTATCACTACTACTTTCTACAAGAACCTGTTTGCTAAACATCCAGAAGTTAGACCATTGTTCGATATGGGCAGACAAGAATCTCTAGAACAACCAAAGGCTTTGGCTATGACTGTCTTGGCTGCTGCTCAGAATATCGAGAATTTGCCAGCAATCTTGCCTGCTGTTAAGAAGATCGCTGTTAAGCATTGTCAAGCTGGTGTTGCTGCAGCTCATTACCCTATTGTTGGTCAAGAATTGTTGGGTGCTATCAAAGAGGTTCTAGGTGATGCAGCTACTGATGATATCTTGGATGCTTGGGGTAAGGCTTATGGCGTTATTGCTGATGTCTTTATCCAAGTTGAGGCTGATTTGTACGCTCAAGCTGTTGAATAG.

[0099]

[0100] In some embodiments of the present invention, in the above application, the sequence of the HUT1 gene is as shown in SEQ ID NO:36: Ctacgcagattttgccttcggtatattagccttcttcttgttgagtgcttcccaagtgattccaccaaatactataaacatccccacccattgctggaaacgtacactcttaccgaagacaataatactcaaaatcatcgagaccattttcctggtgactgttatcatgatcaaaactaaagagccaaattgttctagagtatagaaaataaagcattgtcccatagcgccacagaacgaataaagcattaaatagccccacacttgtgggtccatcgtcaatacagaaacggcattatcccattgtttgcagtcgatcacaataaaatacaaaatattccacaatatcacgaagaggttcagtgtaaacatcaagtgtgcacctgttatcaaagtttgttttcccttttctttggccttattggcctttagtagcttatcttgggtggcgttggtcaatccatcaaggaataaactagagaaaagtagtccaaacccttgtaatttgttatcatttccgctctcattaaaggatctcttcaactttttaccatcgttgccacctatagtgaaaatagtgacaccgagacttaccaagagagctacaacttttttttggcttgctatgggcgtcctatacaaaagcaaatgcaccaacaacacggggatcatcttgcatgactttgctaacatgtaagtgagataatccacgtgctttaaagaagttgtagccagcgggcctgaactactctgtgtaaatgatatcaacatcaattgtttccaatgatctttaatcatttttctgggcggatattccaccttcttccagtttaagtacaggtagcccatcatcattgccacagaagcttgtatgagggatattacattagggaattgaaactttcccatggagtttggccaggttcttgtagccaaaggctcctgtactaatgcccacgtcaaaaaagtagcatatataccaatcgcacagatcaccaaactggatgtacttcccgccat。

[0101] The present invention also provides an expression module, including: one or more of the first expression module to the fourteenth expression module, and the fifteenth expression module to the twenty-third expression module;

[0102] The first expression module includes: the TAL gene used in the above application;

[0103] The second expression module includes: the PAL gene of the above application;

[0104] The third expression module includes: the C4H gene used above;

[0105] The fourth expression module includes: the ATR2 gene used above;

[0106] The fifth expression module includes: the CYB5 gene used above;

[0107] The sixth expression module includes: the ARO4 of the above application K229L Gene;

[0108] The seventh expression module includes: the ARO7 of the above application G141S Gene;

[0109] The eighth expression module comprises: the aroL gene of the above application;

[0110] The ninth expression module comprises: the PDH1 gene used above;

[0111] The tenth expression module comprises: the ROMT-9 of the above application N135T / I324M Gene;

[0112] The eleventh expression module includes: the MET6 gene used above;

[0113] The twelfth expression module includes: the SAH1 gene used above;

[0114] The thirteenth expression module includes: the ADO1 gene used above;

[0115] The fourteenth expression module includes: the MET13 gene and the MTHFR gene used above;

[0116] The fifteenth expression module includes: the UGT73C6 gene used above;

[0117] The sixteenth expression module includes: the EXG1 gene used above;

[0118] The seventeenth expression module includes: the 4CL gene used above;

[0119] The eighteenth expression module includes: the GND1 gene of the above application;

[0120] The nineteenth expression module comprises: the Pos5Δ17 gene used above;

[0121] The twentieth expression module comprises: the HUT1 gene of the above application;

[0122] The twenty-first expression module comprises: the PGM1 gene of the above application;

[0123] The twenty-second expression module comprises: the UGP1 gene of the above application;

[0124] The twenty-third expression module includes: the VHb gene used above.

[0125] In some embodiments of the present invention, the above-mentioned expression module further comprises: a promoter and a terminator;

[0126] The promoter includes: TEF1 , P GPM1 , P TPI1 and P TDH3 One or more of;

[0127] The terminator includes: ADH1 , T TEF2 , T CPS1 and T PGK1 One or more of .

[0128] In some embodiments of the present invention, in the above expression module, the P TEF1The sequence is shown in SEQ ID NO: 16: Atagcttcaaaatgtttctactccttttttactcttccagattttctcggactccgcgcatcgccgtaccacttcaaaacacccaagcac agcatactaaatttcccctctttcttcctctagggtgtcgttaattacccgtactaaaggttttggaaaagaaaaaagagaccgcctcgtttcttttcttcgtcgaaaaaggcaataaaaatttttatcacgtttctttttcttgaaaattttttttttttg attttttctctttcgatgacctcccattgatatttaagttataataaacggtcttcaatttctcaagtttcagtttcattttcttgttctattacaacttttttacttcttgctcattagaaagaaagcatagcaatctaatctaagttttaattacaaa.

[0129] In some embodiments of the present invention, in the above expression module, the P GPM1The sequence is shown in SEQ ID NO: 17: Tagtcgtgcaatgtatgactttaagatttgtgagcaggaagaaaagggagaatcttctaacgataaacccttgaaaaactgggtag actacgctatgttgagttgctacgcaggctgcacaattacacgagaatgctcccgcctaggatttaaggctaagggacgtgcaatgcagacgacagatctaaatgaccgtgtcggtgaagtgttcgccaaacttttcggttaacacatgcagtgatgcacgcgcgatggtgctaagttacatatatatatatatatatatatatatatatatatagccatagtgatgtctaagtaacctttatggtatatttcttaatgtggaaagatactagcgcgcgcacccacacacaagcttcgtcttttcttgaagaaaagaggaagctcgctaaatgggattccactttccgttccctgccagctgatggaaaaaggttagtggaacgatgaagaataaaaagagagatccactgaggtgaaatttcagctgacagcgagtttcatgatcgtgatgaacaatggtaacgagttgtggctgttgccagggagggtggttctcaacttttaatgtatggccaaatcgctacttgggtttgttatataacaaagaagaaataatgaactgattctcttcctccttcttgtcctttcttaattctgttgtaattaccttcctttgtaattttttttgtaattattcttcttaataatccaaacaaacacacatattacaata。

[0130] In some embodiments of the present invention, in the above expression module, the P TPI1The sequence is shown in SEQ ID NO: 18: Tatatctaggaacccatcaggttggtggaagattacccgttctaagacttttcagcttcctctattgatgttacacctggacacccctt ttctggcatccagtttttaatcttcagtggcatgtgagattctccgaaattaattaaagcaatcacacaattctctcggataccacctcggttgaaactgacaggtggtttgttacgcatgctaatgcaaaggagcctatatacctttggctcggctgctgtaacagggaa tataaagggcagcataatttaggagtttagtgaacttgcaacatttactattttcccttcttacgtaaatatttttctttttaattctaaatcaatctttttcaatttttgtttgtattcttttcttgcttaaatctataactacaaaaaacacatacataaactaaaa.

[0131] In some embodiments of the present invention, in the above expression module, the P TDH3The sequence is as shown in SEQ ID NO:19: Agtttatcattatcaatactgccatttcaaagaatacgtaaataattaatagtagtgattttcctaactttatttagtcaaaaaattagcctt ttaattctgctgtaacccgtacatgcccaaaatagggggcgggttacacagaatatataacatcgtaggtgtctgggtgaacagtttattcctggcatccactaaatataatggagcccgctttttaagctggcatccagaaaaaaaaagaatcccagcaccaaaatattgttttcttcaccaaccatcagttcataggtccattctcttagcgcaactacagagaacaggggcacaaacaggcaaaaaacgggcacaacctcaatggagtgatgcaacctgcctggagtaaatgatgacacaaggcaattgacccacgcatgtatctatctcattttcttacaccttctattaccttctgctctctctgatttggaaaaagctgaaaaaaaaggttgaaaccagttccctgaaattattcccctacttgactaataagtatataaagacggtaggtattgattgtaattctgtaaatctatttcttaaacttcttaaattctacttttatagttagtcttttttttagttttaaaacaccaagaacttagtttcgaataaacacacataaacaaacaaa。

[0132] In some embodiments of the present invention, in the above expression module, the T ADH1The sequence is shown in SEQ ID NO:20: GCGAATTTCTTATGATTTATGATTTTTATTATTAAATAAGTTATAAAAAAAATA AGTGTATACAAATTTTAAAGTGACTCTTAGGTTTTTAAAACGAAAATTCTTATTCTTGAGTAACTCTTTCCTGTAGGTCAGGTTGCTTTCTCAGGTATAGCATGAGGTCGCTCTTATTGACCACACCTCTACCGGCATGCCGAGCAAATGCCTGCAAATCGCTCCCCATTTCAC CCAATTGTAGATATGCTAACTCCAGCAATGAGTTGATGAATCTCGGTGTGTATTTTATGTCCTCAGAGGACAACACCTGTTGTAATCGTTCTTCCACACGGATCCACAGCCTAGCCTTCAGTTGGGCTCTATCTTCATCGTCATTCATTGCATCTACTAGCCCCTTACCTGAG.

[0133] In some embodiments of the present invention, in the above expression module, the T TEF2The sequence is shown in SEQ ID NO: 21: gagtaataattattgcttccatataatatttttatatacctcttatttttatgtattagttaattaagtatttttatctatctgcttatcattttcttttc atatagggggggttggtgttttcttgcccatcagattgatgtcctccaactcggcactattttacaaagggtttttttgtaagagaaggagaagacagat actaaaccatacgttatactcgaaacaaaaaaaaaaaaatggaaaaagctgctatcaacaaaagacggcctcatcaaacctaaagaaaccatgtcagcgta tgtatataccttgtaatttacgtttccttaaatcttctttctactaacgttttcattattctatactctatgaccaataaaaacagactgtactttcaaaatttacccagtaggccagcaaataaagaaaattataccagattacttctgaaacacattaatcccaacaacaagtatgccattaatccgtcgctacccc.

[0134] In some embodiments of the present invention, in the above expression module, the T CPS1The sequence is shown in SEQ ID NO:22: Gcgcaatgattgaatagtcaaagattttttttttttaattttttttttttaatttttttttttttcatagaactttttatttaaataaatcacgtctata tatgtatcagtataacgtaaaaaaaaaaacaccgtcagttaaacaaaacataaataaaaaaaaaagaagtgtcaaatcaagtgtcaaatcaaaatttaaatgatgatgataatatgaccatacaatgacttaaatcaaatcaaaaccac ttgcgtaaaggcagtgaatatggccaaaatataataccatacaccgttttgcatcttcgttaaagcaacaccattcgacttcgaggtggtcgaaggcgcagtagcagaaatgctcatcaattgagaagaataggtttcgttttctggaa.

[0135] In some embodiments of the present invention, in the above expression module, the T PGK1 The sequence is shown in SEQ ID NO:23: Attgaattgaattgaaatcgatagatcaatttttttcttttctctttccccatcctttacgctaaaataatagtttattttattttttgaatattttt tatttatatacgtatatatagactattatttatcttttaatgattattaagatttttattaaaaaaaaattcgctcctcttttaatgcctttatgcagttttttttt cccattcgatatttctatgttcgggttcagcgtattttaagtttaataactcgaaaattctgcgttcgttaaagctttcgagaaggatattatttcgaa ataaaccgtgttgtgtaagcttgaagcctttttgcgctgccaatattcttatccatctattgtactctttagatccagtatagtgtattcttcct.

[0136] In some embodiments of the present invention, in the above expression modules, the first expression module is expressed at the above PDC5 site;

[0137] The second expression module, the third expression module, the fourth expression module and the fifth expression module are expressed at the TKL2-TEF2 site;

[0138] The sixth expression module and the seventh expression module are expressed at the YHRCdelta14 site;

[0139] The eighth expression module and the ninth expression module are expressed at the YORWdelta17 site;

[0140] The tenth expression module is expressed at the ARO10 site and the HO site;

[0141] The eleventh expression module, the twelfth expression module, the thirteenth expression module and the fourteenth expression module are expressed at the YNRCdelta9 site;

[0142] The fifteenth expression module is expressed at the YERCdelta8 site;

[0143] The seventeenth expression module is expressed at the HO site;

[0144] The eighteenth expression module and the nineteenth expression module are expressed at the YMRWdelta15 site;

[0145] The twenty-first expression module and the twenty-second expression module are expressed at the YARCdelta8 site;

[0146] The twenty-third expression module is expressed at the YCRWdelta12 site.

[0147] The present invention also provides a strain, into which the above expression module is introduced.

[0148] The present invention also provides the use of the above expression module and / or the above strain in the preparation of homoeriodictyol 7-O-glucoside.

[0149] The present invention also provides a method for preparing homoeriodictyol 7-O-glucoside, and the homoeriodictyol 7-O-glucoside is obtained by inoculating and culturing the above strain.

[0150] The beneficial effects of the present invention include:

[0151] (1) The present invention realizes the biosynthesis of homoeriocarb 7-O-glucoside for the first time.

[0152] (2) The present invention screens out a glycosyltransferase that can act on the 7-hydroxyl group of homoeriocarb.

[0153] (3) The present invention achieves the highest titer of de novo synthesis of homoeriocarb 7-O-glucoside. BRIEF DESCRIPTION OF THE DRAWINGS

[0154] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0155] Figure 1 The pathway for the de novo synthesis of homoeriochoride 7-O-glucoside is shown;

[0156] Figure 2 The results showed that the production of eriodictyol was increased;

[0157] Figure 3 The results showed that the yield of eriodictyol was increased;

[0158] Figure 4 Effects of different glycosyltransferases on the yield of homoeriodictyol 7-O-glucoside

[0159] Figure 5 The introduction of glycosyltransferases, knockout of glycoside hydrolysis genes, and overexpression of rate-limiting enzymes were shown;

[0160] Figure 6 It is shown that NADPH regeneration is regulated to eliminate intermediate accumulation;

[0161] Figure 7 The results showed that the production of homoeriocarb 7-O-glucoside can be increased by regulating UDP-glucose regeneration and controlling cell growth;

[0162] Figure 8 The fermentation conditions of strain YHG026 are shown. DETAILED DESCRIPTION

[0163] The invention discloses application of recombinant saccharomyces cerevisiae in producing homoeriodictyol 7-O-glucoside by utilizing glucose.

[0164] It should be understood that the expression "one or more of..." includes each of the items recited after the expression individually and in various different combinations of two or more of the recited items, unless otherwise understood from the context and usage. The expression "and / or" in combination with three or more recited items should be understood to have the same meaning, unless otherwise understood from the context.

[0165] The use of the terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, for example not excluding other unrecited elements or steps, unless otherwise specifically stated or otherwise understood from the context.

[0166] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the present invention remains operable. In addition, two or more steps or actions may be performed simultaneously.

[0167] The use of any and all examples or exemplary language, such as "for example" or "including", herein is intended only to better illustrate the invention and does not limit the scope of the invention unless otherwise claimed. No language in this specification should be construed as indicating that any non-claimed element is essential to the practice of the invention.

[0168] In addition, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values ​​in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, quantities, values ​​and percentages used in this disclosure are modified by "about". Here, "about" generally means that the actual value is within plus or minus 10%, 5%, 1% or 0.5% of a specific value or range.

[0169] Example of ROMT-9 N135T / I324M The method of integrating genes into the ARO10 site of the yeast genome mainly utilizes CRISPR and homologous recombination technology.

[0170] First build ROMT-9 N135T / I324M Gene expression cassette: P TPI1 -ROMT-9 N135T / I324M -T CPS1 .

[0171] Promoter P TPI1 The yeast genome was used as a template and primers: tatatctaggaacccatcaggt (as shown in SEQ ID NO: 37) and ttttagtttatgtatgtgttttttgtagt (as shown in SEQ ID NO: 38) were used for amplification. The selection principle of the upper primer in the amplification primer is to select a primer of 17-30 bp at the 5' end of the provided promoter sequence, and to ensure that its annealing temperature Tm value is between 52-55° C. The selection principle of the lower primer is to select a primer at the 3' end of the promoter sequence, and the length and Tm value are consistent with the upper primer selection principle, but the Tm value difference between the upper and lower primers must not exceed 5° C.

[0172] ROMT-9 N135T / I324M The gene (synthesized by Qingke Biotechnology Co., Ltd.) was amplified using primers aaacacatacataaactaaaaGCATGG GTTCTACAGCAGCA (as shown in SEQ ID NO: 39) and CTTGGGCTATTGAATTCACTAAGT AAGCgcgcaatgattgaatagtc (as shown in SEQ ID NO: 40).N135T / I324M The 5' ends of the upper and lower primers carry 20bp regions homologous to the promoter and terminator, respectively. Gene amplification primers consist of two parts, one part is homologous to the gene, and the other part is homologous to the promoter or terminator element. The selection principle of the part homologous to the gene is consistent with the selection principle of the promoter amplification primer. After the selection is completed, add 20-30bp homologous to the downstream end of the promoter to the 5' end of the upper primer of the gene (the Tm value of this part is above 50°C), and add 20-30bp homologous to the upstream front end of the terminator to the 5' end of the lower primer of the gene (the Tm value of this part is above 50°C).

[0173] Terminator T CPS1 The yeast genome was used as a template and primers: gcgcaatgattgaatagtcaaa (shown in SEQ ID NO: 41) and agaataggtttcgttttctggaa (shown in SEQ ID NO: 42) were used for amplification. The selection method of the terminator amplification primers was the same as that of the promoter amplification primers.

[0174] The above three amplified fragments were overlapped by PCR to obtain ROMT-9 N135T / I324M expression cassette.

[0175] Next, the yeast genome was used as a template to amplify the connector fragment used for homologous recombination.

[0176] The selection principle of Linker1-1 is 400bp upstream of the genomic insertion site. The selection principle of amplification primers is consistent with the above promoter selection principle. It should be noted that the 5' end of the lower primer of Linker1-1 needs to add 20-30bp homologous to the front end of the upstream promoter (the Tm value of this part is above 50°C). Linker1-1 is amplified with primers CATTTGGTAGTAGGCT TAGGC (as shown in SEQ ID NO:43) and AGATAACAAAGAAACTCCCTTAAGCtcttgcccatcag attgatg (as shown in SEQ ID NO:44), and the lower primer carries 20bp homologous to the promoter.

[0177] The selection principle of Linker2-1 is 400bp downstream of the genomic insertion site. The selection principle of amplification primers is consistent with the above promoter selection principle. It should be noted that the 5' end of the upper primer of Linker2-1 needs to add 20-30bp homologous to the most downstream end of the terminator (the Tm value of this part is above 50°C). Linker2-1 is amplified using primers aagaataggtttcgttttctggaaCT TGTGGGCGCAATTATAAAAC (as shown in SEQ ID NO:45) and GCAGACATTTAGCAGATG TAGG (as shown in SEQ ID NO:46), and the upper primer has 20bp homologous to the terminator.

[0178] Overlap PCR was performed between linker1-1 and the promoter fragment, and overlap PCR was performed between linker2-1 and the terminator fragment to obtain linker1 and linker2, respectively.

[0179] Next, search for the first 20 bp of the pam sequence (NGG) at the ARO10 site as the gRNA, search for the target insertion site on the website https: / / yeastgenome.org / , and obtain the sequence of the insertion site. The specific selection method is to enter the sequence of the insertion site into the "Target asequence" input box of the website https: / / www.atum.bio / eCommerce / cas9 / input, select "Saccharomyces cerevisiae" for species, select "NGG" for PAM, and select "Wild-type Cas9" for Iwant. After the settings are completed, select search and select the gRNA sequence with the highest score in the results.

[0180] In this example, the gRNA is: CGCTTGCTCGGTAGCCTACT (as shown in SEQ ID NO: 47). Next, the CRISPR-gRNA-Cas9-his plasmid was combined with ROMT-9 N135T / I324MThe expression cassette, linker1, and linker2 were transformed into yeast, and then spread on yeast basal medium (SC-his) and cultured for 3-4 days to obtain a recombinant yeast strain. The first pair of verification primers were found upstream of the insertion site and the gene, and the length of the verification interface 1 was about 1000bp. The second pair of verification primers were found downstream of the insertion site and the gene, and the length of the verification interface 2 was about 1000bp. The selection method of the verification primers is to select a 20-30bp verification upper primer (Tm value at 52-55°C) about 100bp upstream of linker1-1 as the upper primer of the first pair of verification primers. The lower primer of the first pair of verification primers is selected in the upstream part of the inserted gene fragment, and the length and Tm value are consistent with the above. Note that the sequence length separated by this pair of primers is about 1000-2000bp. Select a 20-30bp verification upper primer (Tm value at 52-55°C) about 100bp downstream of linker2-1 as the lower primer of the second pair of verification primers. The upper primer of the second pair of verification primers is selected in the downstream part of the inserted gene fragment, and the length and Tm value are consistent with the above. Note that the sequence length between this pair of primers is about 1000-2000bp.

[0181] The first pair of verification primers in this example are: ACACCTCATGTAGCTTCCTTATTAA (as shown in SEQ ID NO: 48), TGCTGCTGTAGAACCCAT (as shown in SEQ ID NO: 49). The second pair of verification primers are: GAGA GAATTCAGAGAATTGGCT (as shown in SEQ ID NO: 50), CTTTGTTAGAGCCAATGATT TCG (as shown in SEQ ID NO: 51).

[0182] The linker sequence selection criteria in the present invention are: for genome-integrated genes, the linker selects a fragment 400 bp upstream and downstream of the site; for knocked-out genes, the linker selects a fragment 400 bp upstream and downstream of the knocked-out gene.

[0183] According to the above method, ROMT-9 N135T / I324M The gene was integrated into the yeast genome at the ARO10 locus.

[0184] The integration of the expression cassette into the gene locus in Examples 1 to 7 of the present invention is the same as the above method, except that the elements in the expression cassette are replaced.

[0185] The selection method of linker1 and linker2 for gene knockout is to use the upstream and downstream 400bp of the gene as linker1 and linker2 respectively. The design principle of amplification primers is that the selection method of linker1 upper primer and linker2 upper and lower primer is consistent with the primer selection method of the promoter mentioned above. It should be noted that the down primer of Linker1 is divided into two parts, one part is homologous to linker1, and the other part is homologous to linker2. Specifically, the part homologous to linker1 is selected according to the selection method of promoter amplification primers, and 20-30bp (the Tm value of this part is above 50°C) is added to the 5' end of the part with a sequence homologous to the front end of linker2 upstream. After PCR amplification of the two linkers, overlap PCR is performed on linker1 and linker2. Used as a fragment for gene knockout.

[0186] The selection method of gene knockout verification primers is to select 20-30bp verification primer (Tm value at 52-55℃) about 100bp upstream of linker1; select 20-30bp verification primer (Tm value at 52-55℃) about 100bp downstream of linker2. Therefore, if the gene is not knocked out, the length of the fragment amplified by the two primers is 1000bp + gene length; if it is knocked out, the length of the amplified fragment is about 1000bp.

[0187] The gene knockout in Examples 1 to 7 of the present invention is the same as the above method.

[0188] In Examples 1 to 7 of the present invention, all the raw materials and reagents used can be purchased from the market.

[0189] The present invention will be further described below in conjunction with embodiments:

[0190] Example 1

[0191] The present invention firstly realizes the de novo synthesis of homoeriodictyol. Firstly, a pathway for synthesizing p-coumaric acid from tyrosine and phenylalanine is constructed in the Yeri001 strain (derived from patent application number: 202310747742.X) that can produce homoeriodictyol from previous research. The specific method is as follows:

[0192] The expression cassette of tyrosine ammonia lyase TAL from Flavobacterium johnsonii (including promoter P TEF1 -TAL gene-terminator T ADH1 ) was integrated into the genomic locus PDC5 of Yeri001 (i.e., the entire PDC5 gene was deleted) to obtain the YTAL001 strain, and then the phenylalanine ammonia lyase PAL (including: P TEF1 -PAL gene-terminator TADH1 ), trans-cinnamate 4-monooxygenase C4H (including: promoter P GPM1 -C4H gene-terminator T TEF2 ), cytochrome P450 reductase 2ATR2 (including: promoter P TPI1 -ATR2 gene-terminator T CPS1 ), an expression cassette of cytochrome b5 from Saccharomyces cerevisiae (including: promoter P TDH3 -CYB5 gene-terminator T PGK1 ) was integrated between the genomic loci TKL2 and TEF2 to obtain the YTP001 strain.

[0193] Example 2

[0194] This example strengthens the de novo synthesis of eriodictyol and optimizes the shikimate pathway of the above recombinant strain. The feedback-insensitive mutant ARO4 of 3-deoxy-D-arabinoheptulose 7-phosphate synthase K229L Expression cassette (including promoter P GPM1 -ARO4 K229L Gene-Terminator T TEF2 ) and the chorismate mutase feedback-insensitive mutant ARO7 G141S Expression cassette (including promoter P TPI1 -ARO7 G141S Gene-Terminator T CPS1 ) was integrated into the genomic locus YHRCdelta14 (i.e., the entire sequence of this locus was deleted) to release the feedback inhibition, and the YTP002 strain was obtained. Then, the expression cassette of the shikimate kinase aroL from Escherichia coli (including: promoter P TDH3 -aroL gene-terminator T PGK1 ) and an expression cassette of prephenate dehydrogenase PDH1 from Medicago truncatula (including: promoter P GPM1 -PDH1 gene-terminator T TEF2 ) was integrated into the genomic site YORWdelta17 (i.e., the entire sequence of this site was deleted) to strengthen the rate-limiting step in the shikimate pathway and obtain the YTP004 strain.

[0195] Table 1

[0196] strain Eriochoridol production YTAL001 15.2mg / L YTP001 110.0mg / L YTP002 130.8mg / L YTP004 209.2mg / L

[0197] The data in Table 1 correspond to Figure 2 .

[0198] Example 3

[0199] After strengthening the synthesis pathway of eriodictyol, ROMT-9 was integrated into the genomic locus ARO10 of the above strain (i.e., the entire sequence of this locus was deleted).N135T / I324M Expression cassette (including promoter P TPI1 -ROMT-9 N135T / I324M Gene-Terminator T CPS1 ), obtain the YTP007 strain, and integrate the yeast endogenous gene homocysteine ​​S-methyltransferase MET6 (including: promoter P TPI1 -MET6 gene-terminator T CPS1 ), S-adenosyl-l-cysteine ​​hydrolase SAH1 (including: promoter P GPM1 -SAH1 gene-terminator T TEF2 ), adenosine kinase ADO1 (including: promoter P TEF1 -ADO1 gene-terminator T ADH1 ), methylenetetrahydrofolate reductase MET13 and a chimeric expression cassette of methylenetetrahydrofolate reductase MTHFR from Arabidopsis thaliana (including: promoter P TDH3 -MET13 gene-MTHFR gene-terminator T PGK1 ), and obtained the YTP008 strain. The above steps achieved the construction of a pathway for the de novo synthesis of homoeriodictyol.

[0200] Table 2

[0201] strain p-Coumaric acid yield Eriochoride production High eriodictyol production YTP007 10.6mg / L 35.9mg / L 137.6mg / L YTP008 35.5mg / L 6.6mg / L 174.0mg / L

[0202] The data in Table 2 correspond to Figure 3 .

[0203] Example 4

[0204] First, glycosyltransferases were screened. The glycosyltransferases screened in the process included: DicGT4 from Carnation, AtGT2, UGT73C6 and UGT73B2 from Arabidopsis, and NtGT2 from tobacco. The expression cassettes of the above genes (promoter PTEF1, terminator TADH1) were transformed into strain YTP008, fermented in YPD medium for 48 hours, and the yield of homoeriocarp 7-O-glucoside was compared. The results are as follows:

[0205] Table 3

[0206] Glycosyltransferase Yield of homoeriocarb 7-O-glucoside (mg / L) DicGT4 19.7 AtGT2 68.4 NtGT2 80.7 UGT73C6 82.4 UGT73B2 98.2

[0207] The data in Table 3 correspond to Figure 4 .

[0208] Next, in order to use an effective glycosyltransferase to achieve the synthesis of homoeriocarbol 7-O-glucoside, the expression cassette of the screened glycosyltransferase UGT73C6 from Arabidopsis thaliana (including: promoter P TEF1 -UGT73C6 gene-terminator TADH1 ) was integrated into the genomic site YERCdelta8 of the above-mentioned recombinant strain (i.e., the entire sequence of the site was deleted) to obtain the YHG001 strain. In order to achieve efficient accumulation of homoeriocarbol 7-O-glucoside, the endogenous yeast glucosidase EXG1 (accession number: SGD:S000004291) was knocked out to obtain the YHG005 strain. And overexpressed the key rate-limiting enzyme 4CL in the entire pathway (derived from patent application number: 202310747742.X, including: promoter P TPI1 -4CL gene-terminator T CPS1 ), ROMT-9 N135T / I324M (derived from patent application number: 202310747742.X, including: promoter P TPI1 -ROMT-9 N135T / I324M Gene-Terminator T CPS1 ), the expression cassettes of the two enzymes were integrated into the genomic site HO (i.e., the entire sequence of the site was deleted) to eliminate the accumulation of the intermediates p-coumaric acid and eriodictyol, and the YHG006 strain was obtained.

[0209] Table 4

[0210]

[0211] The data in Table 4 correspond to Figure 5 .

[0212] Example 5

[0213] Since multiple reactions in the de novo synthesis pathway involve the participation of the reduced coenzyme NADPH, the regeneration of NADPH in yeast was strengthened. The expression cassette of the endogenous yeast 6-phosphate glucose dehydrogenase GND1 (including: promoter P TEF1 -GND1 gene-terminator T ADH1 ) and an expression cassette (including: promoter P GPM1 -Pos5Δ17 gene-terminator T TEF2 ) was integrated into the genomic site YMRWdelta15 (i.e., all sequences at this site were deleted) to obtain the YHG013 strain.

[0214] Table 5

[0215]

[0216] The data in Table 5 correspond to Figure 6 .

[0217] Example 6

[0218] Uridine diphosphate glucose (UDP-glucose) is a glycosyl donor for homoeriodictyol glycosylation, so this embodiment strengthens the biosynthesis of UDP-glucose and weakens the intracellular secretion of UDP-glucose.

[0219] The specific method is to knock out the endogenous UDP-galactose transporter HUT1 (accession number: SGD:S000006165) in yeast, and replace the expression cassette of the endogenous phosphoglucomutase (PGM1) in yeast (including: promoter P TEF1 -PGM1 gene-terminator T ADH1 ) and UDP-glucose pyrophosphorylase (UGP1) expression cassette (including: promoter P TPI1 -UGP1 gene-terminator T CPS1 ) was integrated into the genomic site YARCdelta8 (i.e., all sequences at this site were deleted) to obtain the YHG021 strain.

[0220] Example 7

[0221] Finally, in order to optimize the growth of the strain, the expression cassette of bacterial hemoglobin (VHb) from Vitreous Oscillatoria sp. (including: promoter P TEF1 -VHb gene-terminator T ADH1 ) was integrated into the genomic locus YCRWdelta12 (i.e., the entire sequence of this locus was deleted) to obtain the YHG026 strain. Finally, the strain was optimized for fermentation: 100 μL of the bacteria stored at -80°C was inoculated into 5 mL of the synthetic medium SC-URA medium. The culture was carried out overnight at 30°C and 220 rpm. The next morning, the OD of the seeds was measured. 600 Value, based on initial OD 600 The seed culture medium was inoculated into the fermentation medium (30 mL of YPD medium) with an inoculum size of 0.1, and 512 μL of 500 g / L glucose solution was added to the medium at 24 h and 48 h, respectively, to ensure that the final glucose concentration was 40 g / L, and fermented at 30°C and 220 rpm for 72 h.

[0222] Fed-batch fermentation in yeast extract peptone glucose medium yielded 461.7 mg / L homoeriodictyol 7-O-glucoside from 40 g / L glucose.

[0223] Table 6

[0224] strain High yield of eriodictyol 7-O-glucoside YHG021 360.3mg / L YHG026 394.0mg / L

[0225] The data in Table 6 correspond to Figure 7 .

[0226] Table 7

[0227] Time High yield of eriodictyol 7-O-glucoside <![CDATA[OD 600 ]]> 0h 0 0 24h 157.0mg / L 15.8 48h 368.7mg / L 21.6 72h 423.4mg / L 22.6 96h 461.7mg / L 23.1

[0228] The data in Table 7 correspond to Figure 8 .

[0229] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of integration site as target in the preparation of homoeriodictyol 7-O-glucoside; The integration sites include: One or more of the PDC5 site, TKL2-TEF2 site, YHRCdelta14 site, YORWdelta17 site, ARO10 site, YNRCdelta9 site, YERCdelta8 site, HO site, YMRWdelta15 site, YARCdelta8 site and YCRWdelta12 site.

2. Use of expressed genes and / or knocked-out genes in the preparation of homoeriodictyol 7-O-glucoside; The expressed genes include: exogenous expressed genes and / or endogenous expressed genes; The exogenous expression genes include: TAL gene, PAL gene, C4H gene, ATR2 gene, aroL gene, PDH1 gene, ROMT-9 N135T / I324M one or more of gene, MTHFR gene, UGT73C6 gene, 4CL gene and VHb gene; The endogenous expression genes include: CYB5 gene, ARO4 K229L Gene, ARO7 G141S one or more of gene, MET6 gene, SAH1 gene, ADO1 gene, MET13 gene, GND1 gene, Pos5Δ17 gene, PGM1 gene and UGP1 gene; The knockout genes include: EXG1 gene and / or HUT1 gene.

3. The use according to claim 2, characterized in that The TAL genes have: (1), the nucleotide sequence shown in SEQ ID NO: 1; or (2) a nucleotide sequence obtained by substituting, deleting or adding one or more bases to the nucleotide sequence shown in (1), and having the same or similar function as the nucleotide sequence shown in (1); or (3) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (1) or (2); or The PAL gene has: (4) the nucleotide sequence shown in SEQ ID NO: 2; or (5) a nucleotide sequence obtained by substituting, deleting or adding one or more bases of the nucleotide sequence shown in (4), and having the same or similar function as the nucleotide sequence shown in (4); or (6) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (4) or (5); or The C4H gene has: (7), the nucleotide sequence shown in SEQ ID NO: 3; or (8) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as the nucleotide sequence shown in (7); or (9), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (7) or (8); or The ATR2 gene has: (10), the nucleotide sequence shown in SEQ ID NO: 4; or (11) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (10), and having the same or similar function as the nucleotide sequence shown in (10); or (12) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (10) or (11); or The CYB5 gene has: (13), the nucleotide sequence shown in SEQ ID NO: 5; or (14) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (13), and having the same or similar function as the nucleotide sequence shown in (13); or (15) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (13) or (14); or The ARO4 K229L Genes have: (16), the nucleotide sequence shown in SEQ ID NO: 6; or (17) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (16), and having the same or similar function as the nucleotide sequence shown in (16); or (18), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (16) or (17); or The ARO7 G141S Genes have: (19), the nucleotide sequence shown in SEQ ID NO:7; or (20) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (19), and having the same or similar function as the nucleotide sequence shown in (19); or (21), a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (19) or (20); or The aroL gene has: (22), the nucleotide sequence shown in SEQ ID NO: 8; or (23) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (22), and having the same or similar function as the nucleotide sequence shown in (22); or (24), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (22) or (23); or The PDH1 gene has: (25), the nucleotide sequence shown in SEQ ID NO:9; or (26) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (25), and having the same or similar function as the nucleotide sequence shown in (25); or (27) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (25) or (26); The UGT73C6 gene has: (28), the nucleotide sequence shown in SEQ ID NO: 10; or (29) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (28), and having the same or similar function as the nucleotide sequence shown in (28); or (30), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (28) or (29); The GND1 gene has: (31), the nucleotide sequence shown in SEQ ID NO: 11; or (32) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (31), and having the same or similar function as the nucleotide sequence shown in (31); or (33) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (31) or (32); The Pos5Δ17 gene has: (34), the nucleotide sequence shown in SEQ ID NO: 12; or (35) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (34), and having the same or similar function as the nucleotide sequence shown in (34); or (36) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (34) or (35); The PGM1 gene has: (37), the nucleotide sequence shown in SEQ ID NO: 13; or (38) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (37), and having the same or similar function as the nucleotide sequence shown in (37); or (39), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (37) or (38); The UGP1 gene has: (40), the nucleotide sequence shown in SEQ ID NO: 14; or (41) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (40), and having the same or similar function as the nucleotide sequence shown in (40); or (42), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (40) or (41); The VHb gene has: (43), the nucleotide sequence shown in SEQ ID NO: 15; or (44) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (43), and having the same or similar function as the nucleotide sequence shown in (43); or (45) A nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (43) or (44).

4. An expression module, characterized in that include: One or more of the first to fourteenth expression modules, and the fifteenth to twenty-third expression modules; The first expression module comprises: the TAL gene used as claimed in claim 2 or 3; The second expression module comprises: the PAL gene used as claimed in claim 2 or 3; The third expression module comprises: the C4H gene used as claimed in claim 2 or 3; The fourth expression module comprises: the ATR2 gene used as claimed in claim 2 or 3; The fifth expression module comprises: the CYB5 gene used as claimed in claim 2 or 3; The sixth expression module includes: the ARO4 used as claimed in claim 2 or 3 K229L Gene; The seventh expression module comprises: the ARO7 as used in claim 2 or 3 G141S Gene; The eighth expression module comprises: the aroL gene used as claimed in claim 2 or 3; The ninth expression module comprises: the PDH1 gene used as claimed in claim 2 or 3; The tenth expression module comprises: the ROMT-9 as used in claim 2 or 3 N135T / I324M Gene; The eleventh expression module comprises: the MET6 gene used as claimed in claim 2 or 3; The twelfth expression module comprises: the SAH1 gene used as claimed in claim 2 or 3; The thirteenth expression module comprises: the ADO1 gene used as claimed in claim 2 or 3; The fourteenth expression module comprises: the MET13 gene and the MTHFR gene used as claimed in claim 2 or 3; The fifteenth expression module comprises: the UGT73C6 gene used as claimed in claim 2 or 3; The sixteenth expression module comprises: the EXG1 gene used as claimed in claim 2 or 3; The seventeenth expression module comprises: the 4CL gene used as claimed in claim 2 or 3; The eighteenth expression module comprises: the GND1 gene used as claimed in claim 2 or 3; The nineteenth expression module comprises: the Pos5Δ17 gene used as claimed in claim 2 or 3; The twentieth expression module comprises: the HUT1 gene used as claimed in claim 2 or 3; The twenty-first expression module comprises: the PGM1 gene used as claimed in claim 2 or 3; The twenty-second expression module comprises: the UGP1 gene used as claimed in claim 2 or 3; The twenty-third expression module comprises: the VHb gene used as claimed in claim 2 or 3.

5. The expression module according to claim 4, characterized in that Also includes: promoters and terminators; The promoter includes: TEF1 , P GPM1 , P TPI1 and P TDH3 One or more of; The terminator includes: ADH1 , T TEF2 , T CPS1 and T PGK1 One or more of .

6. The expression module according to claim 4 or 5, characterized in that The first expression module is expressed at the PDC5 site as claimed in claim 1; The second expression module, the third expression module, the fourth expression module and the fifth expression module are expressed at the TKL2-TEF2 site according to claim 1; The sixth expression module and the seventh expression module are expressed at the YHRCdelta14 site as claimed in claim 1; The eighth expression module and the ninth expression module are expressed at the YORWdelta17 site as claimed in claim 1; The tenth expression module is expressed at the ARO10 site and the HO site as claimed in claim 1; The eleventh expression module, the twelfth expression module, the thirteenth expression module and the fourteenth expression module are expressed at the YNRCdelta9 site according to claim 1; The fifteenth expression module is expressed at the YERCdelta8 site as claimed in claim 1; The seventeenth expression module is expressed at the HO site according to claim 1; The eighteenth expression module and the nineteenth expression module are expressed at the YMRWdelta15 site as claimed in claim 1; The twenty-first expression module and the twenty-second expression module are expressed at the YARCdelta8 site according to claim 1; The twenty-third expression module is expressed at the YCRWdelta12 site as claimed in claim 1.

7. A strain characterized in that The expression module according to any one of claims 4 to 6 is introduced into the chassis strain.

8. Use of the expression module according to any one of claims 4 to 6 and / or the strain according to claim 7 in the preparation of homoeriodictyol 7-O-glucoside.

9. A method for preparing homoeriodictyol 7-O-glucoside, characterized in that: The strain as claimed in claim 7 is inoculated and cultured to obtain the homoeriodictyol 7-O-glucoside.